Brought to you by 
Cambridge Antibody to develop therapeutic MAbs for HGS
Sep 1999
Executive Summary
In exchange for research funding, plus potential milestones and sales royalties, Cambridge Antibody Technology will provide its high-throughput isolation technologies to develop fully human monoclonal antibodies (MAbs) for up to three human proteins from Human Genome Sciences' targets. The two biotechs will focus on a specific fast-track antigen that HGS discovered through its genomics program.
Deal Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cambridge Antibody to develop therapeutic MAbs for HGS
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice